Barclays
AURA icon

Barclays’s Aura Biosciences AURA Stock Holding History

Barclays’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$77.2K Sell
11,540
-57,758
-83% -$331K ﹤0.01% 4141
2025
Q4 		$378K Buy
69,298
+4,366
+7% +$25.9K ﹤0.01% 4011
2025
Q3 		$401K Sell
64,932
-3,619
-5% -$23.7K ﹤0.01% 3939
2025
Q2 		$429K Buy
68,551
+18,156
+36% +$106K ﹤0.01% 3842
2025
Q1 		$295K Sell
50,395
-22,330
-31% -$169K ﹤0.01% 3836
2024
Q4 		$598K Buy
72,725
+11,715
+19% +$110K ﹤0.01% 3716
2024
Q3 		$544K Buy
61,010
+43,897
+257% +$376K ﹤0.01% 3724
2024
Q2 		$129K Sell
17,113
-8,281
-33% -$60.7K ﹤0.01% 3787
2024
Q1 		$199K Sell
25,394
-12,775
-33% -$106K ﹤0.01% 4121
2023
Q4 		$338K Buy
38,169
+33,295
+683% +$282K ﹤0.01% 4128
2023
Q3 		$43.7K Sell
4,874
-22,978
-83% -$247K ﹤0.01% 3924
2023
Q2 		$344K Sell
27,852
-6,565
-19% -$70.2K ﹤0.01% 2975
2023
Q1 		$319K Sell
34,417
-2,102
-6% -$21.8K ﹤0.01% 3546
2022
Q4 		$383K Sell
36,519
-5,525
-13% -$70.3K ﹤0.01% 3475
2022
Q3 		$762K Sell
42,044
-142
-0.3% -$2.15K ﹤0.01% 2417
2022
Q2 		$598K Sell
42,186
-17,511
-29% -$290K ﹤0.01% 2742
2022
Q1 		$1.31M Buy
+59,697
New +$1.14M ﹤0.01% 2191

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Barclays's AURA Position: Q1 2026 in Review

Barclays reduced its Aura Biosciences (AURA) stake by 83% in Q1 2026, selling an estimated $331K and leaving 11,540 shares worth $77.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4141.

Barclays first reported a position in AURA in Q1 2022 and has held it in 17 quarters since. The position peaked at $1.31M in Q1 2022. 126 funds tracked by Wall St. Rank hold AURA as of Q1 2026.

  • Barclays held 11,540 shares of Aura Biosciences worth $77.2K as of Q1 2026.
  • Barclays sold 57,758 Aura Biosciences shares in Q1 2026, an estimated $331K.
  • Aura Biosciences made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4141 holding.
  • Barclays first reported a position in Aura Biosciences in Q1 2022 and has held it in 17 quarters since.
  • Barclays's Aura Biosciences position peaked at $1.31M in Q1 2022.
  • 126 funds tracked by Wall St. Rank held Aura Biosciences as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.